IN CASE YOU MISSED IT… Chairman Scott, Ranking Member Gillibrand Highlight CLEAR LABELS Act in ABC News Interview on Securing U.S. Drug Supply Chain
WASHINGTON, D.C. – Chairman Rick Scott and Ranking Member Kirsten Gillibrand sat down with ABC7’s Lisa Fletcher to discuss their new bipartisan, bicameral CLEAR LABELS Act. This bill would require country-of-origin labeling for prescription medicines and their ingredients, ensuring Americans know exactly where the drugs in their medicine cabinets are produced.
The CLEAR LABELS Act will bring greater transparency to the pharmaceutical supply chain, helping patients, pharmacists, and other purchasers make more informed decisions about the medications they rely on while supporting American jobs, strengthening domestic pharmaceutical manufacturing, and rebuilding a secure and reliable U.S. supply chain so families can have confidence that their medicines are safe, properly regulated, and clearly labeled. Currently, many prescription drugs and their ingredients are manufactured overseas, particularly in Communist China and India, while federal labeling requirements are leaving patients, pharmacists, and healthcare providers in the dark about where these medicines come from.
Watch the full interview HERE or below:
See below to read more about Senator Scott’s bipartisan work as Chairman of the U.S. Senate Special Committee on Aging:
- 03/11/26: Chairman Scott Exposes Communist China’s Dangerous Grip on America’s Medicine Supply; Highlights CLEAR LABELS Act to Increase Transparency
- 03/05/26: Chairman Scott’s CLEAR LABELS Act Garners Bicameral Support with Rep. McCormick in the U.S. House
- 03/04/26: Chairman Scott, Ranking Member Gillibrand Press America’s Pharmacies on U.S. Drug Supply Chain and Country-of-Origin Labeling for Foreign-Made Drugs
- 02/19/26: Chairman Scott Sends Letter to Secretary Hegseth on Securing Generic Drug Supply for Service Members and Veterans
- 02/05/26: Chairman Scott, Ranking Member Gillibrand Introduce CLEAR LABELS Act to Protect American Patients Through Drug Origin Transparency and Stronger Supply Chain Oversight
- 01/29/26: Chairman Scott Calls for Transparency of Foreign-Made Generic Drugs, Announces CLEAR LABELS Act to Require Country-of-Origin Labeling
- 11/20/25: Chairman Scott, Ranking Member Gillibrand Send Letter to VA Secretary on Protecting Veterans’ Pharmaceutical Supply Chains
- 11/19/25: Chairman Scott Leads Aging Hearing on Navigating Path to Restoring U.S. Leadership in Essential Drug Manufacturing
- 11/11/25: Chairman Scott, Ranking Member Gillibrand Send Letter to Major U.S. Pharmacies on Foreign Drug Supply Chain Vulnerabilities
- 10/30/25: Chairman Scott, Ranking Member Gillibrand Send Letter to Pharmaceutical Distributor Executives on Regulatory Oversight of Foreign-Manufactured Generic Drugs
- 10/29/25: Chairman Scott, Ranking Member Gillibrand Send Letter to Group Purchasing Organization Executives on Regulatory Oversight of Foreign-Manufactured Generic Drugs
- 10/24/25: Chairman Scott, Ranking Member Gillibrand Pen Letter to HHS on Dangers of Overreliance on Foreign-Manufactured Generic Drugs and Request Information on HHS’s Efforts to Combat Vulnerabilities
- 10/20/25: Chairman Scott, Ranking Member Gillibrand Release Investigative Report Exposing America’s Dangerous Overreliance on Foreign-Made Generic Drugs, Proposing Bipartisan Policy Recommendations
- 10/08/25: Chairman Scott Leads Aging Committee Hearing on Closing Deadly Generic Drug Loopholes and Rebuilding America’s Essential Medicine Supply
- 09/18/25: Chairman Scott, Ranking Member Gillibrand Pen Bipartisan Letter to FDA Commissioner on Oversight and Safety of Foreign-Manufactured Generic Drugs, Requests Answers on Ties to Forced Labor in China
- 09/17/25: Chairman Scott: U.S. Overdependence on Foreign-Manufactured Generic Drugs Threatens Lives of America’s Seniors & National Security
- 04/01/25: Chairman Scott, Sens. Moody and Justice Ask FDA to Prioritize Foreign & Domestic Drug Quality and Protect Seniors
###